Journals / Journal of Clinical Research in Pediatric Endocrinology / 2016 / Cilt: 8 - Sayı: 3

Pseudotumour Cerebri Presentation in a Child Under the Gonadotropin-Releasing Hormone Agonist Treatment

Pages
365–367
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

We observed pseudotumor cerebri after precocious puberty treatment, a finding for the first time ever seen in childhood.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Gonadotropin-releasing hormone analogues are common treatment option in central precocious puberty in childhood as well as in endometriosis, infertility, and prostate cancer in adults.
📊
Key Findings & Data:We present the case of a girl with precocious puberty treated with triptorelin acetate who developed pseudotumor cerebri after the 4th dose.
💡
Conclusion & Impact:We observed pseudotumor cerebri after precocious puberty treatment, a finding for the first time ever seen in childhood.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Gonadotropin-releasing hormone analogues are common treatment option in central precocious puberty in childhood as well as in endometriosis, infertility, and prostate cancer in adults. Pseudotumor cerebri is a rare side effect observed in adults. We present the case of a girl with precocious puberty treated with triptorelin acetate who developed pseudotumor cerebri after the 4th dose. She had headaches, and her blood pressure was detected to be above the 99 percentile. There were no causes underlying of hypertension such as cardiac, renal, or endocrine. Neurological examination was normal except bilateral papilledema. Cranial magnetic resonance imaging was normal. Cerebrospinal fluid (CSF) opening pressure was elevated. Triptorelin therapy was ceased and acetazolamide was applied; CSF pressure returned to normal. We observed pseudotumor cerebri after precocious puberty treatment, a finding for the first time ever seen in childhood.

🔖

Cite This Article

GÜL, Ü., BAYRAM, A. K., KENDİRCİ, M., HATİPOĞLU, N., OKDEMİR, D., GÜMÜŞ, H., KURTOĞLU, S. (2016). Pseudotumour Cerebri Presentation in a Child Under the Gonadotropin-Releasing Hormone Agonist Treatment. Journal of Clinical Research in Pediatric Endocrinology, Cilt: 8 - Sayı: 3, 365–367. https://ajindex.com/articles/213227

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (4)

  1. Casper RF. Clinical uses of gonadotropin-releasing hormone analogues. CMAJ 1991;144:153-158. Soriano-Guillén L, Argente J. [Central precocious puberty: epidemiology, etiology, diagnosis and treatment]. An Pediatr (Barc) 2011;74: 336.e1-336.e13. Epub 2011 Feb 18 Sagsveen M, Farmer JE, Prentice A, Breeze A. Gonadotrophin- releasing hormone analogues for endometriosis: bone mineral density. Cochrane Database Syst Rev 2003;CD001297. Walker LM, Tran S, Robinson JW. Luteinizing hormone-- releasing hormone agonists: a quick reference for prevalence rates of potential adverse effects. Clin Genitourin Cancer 2013;11: 375-384. Epub 2013 Jul 25 Burris K, Ding CY, Lim GF. Leuprolide acetate-induced generalized papular eruption. J Drugs Dermatol 2014;13:755- 757. Gnanaraj J, Saif MW. Hypersensitivity vasculitis associated with leuprolide (Lupron). Cutan Ocul Toxicol 2010;29:224- 227. Conteduca V, Di Lorenzo G, Tartarone A, Aieta M. The cardiovascular risk of gonadotropin releasing hormone agonists in men with prostate cancer: an unresolved controversy. Crit Rev Oncol Hematol 2013; 86; 42-51. Epub 2012 Oct 23 Calcaterra V, Mannarino S, Corana G, Codazzi AC, Mazzola A, Brambilla P, Larizza D. Hypertension during therapy with triptorelin in a girl with precocious puberty. Indian J Pediatr 2013;80:884-885. Epub 2012 Nov 22 Siomou E, Kosmeri C, Pavlou M, Vlahos AP, Argyropoulou MI, Siamopoulou A. Arterial hypertension during treatment with triptorelin in a child with Williams-Beuren syndrome. Pediatr Nephrol 2014;29:1633-1636. Epub 2014 Mar 7 Nelson K, Ward K, Narang AS. Posttraumatic pseudotumor cerebri in a 4-year-old female. Pediatr Emerg Care 2004;20:460-463.
  2. Kesler A, Fattal-Valevski A. Idiopathic intracranial hypertension in the pediatric population. J Child Neurol 2002;17:745-748.
  3. Tibussek D, Schneider DT, Vandemeulebroecke N, Turowski B, Messing-Juenger M, Willems PH, Mayatepek E, Distelmaier F. Clinical spectrum of the pseudotumor cerebri complex in children. Childs Nerv Syst 2010;26:313-321. Epub 2009 Nov 10 Wolf A, Hutcheson KA. Advances in evaluation and management of pediatric idiopathic intracranial hypertension. Curr Opin Ophthalmol 2008;19:391-397.
  4. Bhatt UK, Haq I, Avadhanam VS, Bibby K. A 43-year-old woman on triptorelin presenting with pseudotumor cerebri: a case report. J Med Case Rep 2012;6:122. Boot JH. Pseudotumour cerebri as a side effect of leuprorelin acetate. Ir J Med Sci 1996;165:60. Arber N, Shirin H, Fadila R, Melamed E, Pinkhas J, Sidi Y. Pseud